falintolol has been researched along with Glioma in 1 studies
*Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) [MeSH]
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Conti, P; Dallanoce, C; De Amici, M; De Micheli, C; Klotz, KN | 1 |
1 other study(ies) available for falintolol and Glioma
Article | Year |
---|---|
Synthesis of new delta 2-isoxazoline derivatives and their pharmacological characterization as beta-adrenergic receptor antagonists.
Topics: Adenylyl Cyclases; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Binding, Competitive; CHO Cells; Chromatography, Thin Layer; Cricetinae; Glioma; Humans; Isoxazoles; Magnetic Resonance Spectroscopy; Pindolol; Propanolamines; Radioligand Assay; Rats; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Tumor Cells, Cultured | 1998 |